Although 2009 is certainly a year to forget - Unquote
Although 2009 is certainly a year to forget - Unquote
Although 2009 is certainly a year to forget - Unquote
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
early-stage<br />
unquote<br />
McPhy’s cleantech focus was a major attraction for the inves<strong>to</strong>rs. The deal marks Sofinnova’s fourth<br />
investment in th<strong>is</strong> sec<strong>to</strong>r, following its funding of DNP Green, Revolt Technology and Neosens.<br />
All contribu<strong>to</strong>rs <strong>to</strong> th<strong>is</strong> round believe solid state hydrogen s<strong>to</strong>rage will address the crucial <strong>is</strong>sue of<br />
sustainable energy s<strong>to</strong>rage.<br />
Company<br />
McPhy <strong>is</strong> a French company founded in January 2008 <strong>to</strong> industrial<strong>is</strong>e and commercial<strong>is</strong>e a new<br />
technology for the solid s<strong>to</strong>rage of hydrogen, in the form of magnesium hydride. The technology<br />
addresses the merchant hydrogen and renewable energy markets.<br />
McPhy owns exclusive rights on a portfolio of unique patents, which results from more than eight <strong>year</strong>s<br />
of research at the CNRS and CEA, in partnership with Joseph Fourier University.<br />
People<br />
Alessio Beverina led the deal for Sofinnova. Bart Diels handled the transaction for Gimv. Florent<br />
Thomann represented Amundi PEF. Pascal Mauberger <strong>is</strong> CEO of McPhy.<br />
Adv<strong>is</strong>ers<br />
Company – Clipper<strong>to</strong>n Finance, Nicolas von Bulow, Thomas Neveux (M&A).<br />
EARLY-STAGE<br />
EyeTechCare<br />
7.5m<br />
Location<br />
Sec<strong>to</strong>r<br />
Founded 2008<br />
Staff 7<br />
Rillieux-la-Pape<br />
Medical<br />
equipment<br />
Crédit Agricole et al. in 7.5m EyeTechCare deal<br />
Transaction<br />
Crédit Agricole Private Equity and insurance company SHAM have provided medical devices developer<br />
EyeTechCare with a 7.5m round of funding.<br />
Crédit Agricole led the round with 4.5m, while SHAM invested 3m. EyeTechCare had already<br />
ra<strong>is</strong>ed 1.2m in 2008 from Crédit Agricole and CEA-Invest<strong>is</strong>sement. The new funds will be used <strong>to</strong><br />
complete the initial clinical trials on humans, as well as <strong>to</strong> establ<strong>is</strong>h the manufacturing facilities and sales<br />
and marketing force required for the company’s first product.<br />
The inves<strong>to</strong>rs believe EyeTechCare’s solution will respond <strong>to</strong> unmet needs in the treatment of glaucoma.<br />
Crédit Agricole, which has been following the company since its inception, was particularly impressed<br />
with the management team’s progress over the last two <strong>year</strong>s.<br />
Company<br />
EyeTechCare was founded in 2008 and <strong>is</strong> based in Rillieux-la-Pape, near Lyon. With a staff of seven<br />
researchers, it special<strong>is</strong>es in non-invasive therapeutic medical devices using ultrasound technology. The<br />
company <strong>is</strong> currently developing an ultrasound-based medical device for the treatment of glaucoma; its<br />
market launch <strong>is</strong> scheduled for early 2011.<br />
People<br />
Alexia Perouse handled the transaction for Crédit Agricole. Olivier Szymkowiak represented SHAM.<br />
Fabrice Romano <strong>is</strong> the chairman of EyeTechCare.<br />
Adv<strong>is</strong>ers<br />
Equity – Morgan Lew<strong>is</strong> Bockius (Legal).<br />
Company – MAGS (Legal); Aelios Finance (Corporate finance).<br />
18 UNQUOTE AUGUST/SEPTEMBER 10 ENTIRE CONTENTS COPYRIGHT 2010 INCISIVE MEDIA INVESTMENTS LTD<br />
www.unquote.com/france